Revolutionizing brain-computer interface technology with a non-surgical approach
Subsense, a Brain-Computer Interface (BCI) company, has officially emerged from stealth mode after securing $17 million in seed funding. Led by Golden Falcon Capital, the round will support Subsense’s development of its non-surgical, nanoparticle-based BCI system.
Key Details:
- Subsense’s BCI aims to provide safe and effective connectivity by utilizing biocompatible nanoparticles to interact with the brain, enhancing the user’s ability to control devices and navigate technology.
- Collaborating with UC Santa Cruz and ETH Zurich, Subsense targets individuals with paralysis, neurological disorders, and conditions like Parkinson’s, Alzheimer’s, and epilepsy.
- The company’s BCI technology enables real-time brain monitoring, and offers potential applications for vision, hearing, motor function recovery, and mental health regulation.
CEO Tetiana Aleksandrova emphasized that their approach addresses the challenges of non-invasive, effective BCI development, aiming to unlock human potential and transform healthcare outcomes.
Follow MEDWIRE.AI for more updates on advancements in brain-computer interfaces and neurological treatment innovations.
